Objective To demonstrate the efficacy, tolerability, and safety of domestic Acarbose tablet compared with Glucobay (Acarbose tablet produced by Bayer company) in patients with type 2 diabetic patients. Method A multicenter randomized controlled parallel-group comparison study was conducted. 177 Chinese type 2 diabetic patients were recruited from 4 clinical centers. The patients were divided randomly into domestic Acarbose tablet (A group) or Glucoby (B group) treatment group. The trial consisted of a 2-4 weeks equilibrated period followed by an 8 week course of treatment. Results 165 patients have finished the trial (81 in A group and 84 in B group). After 4 weeks of treatment, the mean of fasting blood glucose (FBG) in A and B group were reduced 1.61 and 2.08 mmol/L respectively, and mean of postprandial blood glucose (PBG) lowered 5.06 and 5.09mmol/L respectively. After 8 weeks of treatment, the mean of FBG were reduced 1.95 and 2.62mmol/L respectively, and mean of PBG lowered 4.88 and 5.98 mmol/L, respectively, and mean of HbA1c were lowered 1.13% and 1.20% respectively in A and B group. The differences in reduction of FBG, PBG, and HbA1c between A and B group were no statistic significance. The serum triglyceride levels and BMI were decreased significantly in both A, B groups. 3 patients who drinking wine during trial on A group had asymptomatic elevations in serum transaminases that normalized in 2 weeks after stopped drinking and Acarbose withdrawal. Flatulence was the most common side effect. Conclusions In this multicenter study, domestic Acarbose tablet 50 mg t.i.d. was an effective, safe, and generally well-tolerated therapy as similar as Glucobay in type 2 diabetic patients.
ObjectiveThis study aimed to construct a Nomogram predictive model to assess the prognosis of patients with viral pneumonia complicated by diabetes mellitus.MethodsWe retrospectively collected data from patients with viral pneumonia who visited our hospital from January 2023 to February 2024 and divided them into diabetes and non-diabetes groups based on the presence of diabetes. Clinical data were collected and intergroup differences were analyzed. Subsequently, factors with statistical significance (P<0.05) were selected for univariate and multivariate Logistic regression analysis in the diabetes group to identify risk factors affecting patient survival. Based on the regression analysis results, a linear model was constructed to predict the survival risk of patients. Additionally, calibration curves and decision curve analysis (DCA) were plotted to assess the predictive accuracy and clinical net benefit of the model.ResultsThe study found significant intergroup differences in age (age), cough, dyspnea, respiratory rate at admission, heart rate, body temperature, and laboratory test results (including blood glucose Glu, glycated hemoglobin HbA1c, neutrophil ratio Neu, C-reactive protein Crp, etc.). Multivariate Logistic regression analysis confirmed that age (age), B-type natriuretic peptide (Bnp), neutrophil ratio (Neu), and lactate (Lac) are independent risk factors affecting the survival of patients with viral pneumonia and diabetes.The constructed nomogram prediction model was evaluated. The calibration curve demonstrated a high degree of consistency between the predicted probabilities and actual outcomes, with a non-significant Hosmer-Lemeshow test result (P>0.05). Decision curve analysis further showed that the model yielded no significant clinical net benefit at extreme probability thresholds, whereas it provided substantial clinical net benefit across all other threshold ranges. Collectively, these findings indicate that the model exhibits high predictive accuracy and holds significant value for clinical application. ConclusionsAge, serum B-type natriuretic peptide, neutrophil ratio, and lactate are independent risk factors for the survival of patients with viral pneumonia complicated by diabetes. The Nomogram predictive model constructed based on these factors has clinical value for prognosis assessment.